iRadimed Corporation (NASDAQ:IRMD) is scheduled to issue its quarterly earnings data before the market opens on Monday, October 30th. Analysts expect the company to announce earnings of $0.03 per share for the quarter. iRadimed Corporation has set its Q3 guidance at $0.02-0.03 EPS.

iRadimed Corporation (NASDAQ:IRMD) last posted its earnings results on Friday, July 28th. The medical equipment provider reported $0.06 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.07. iRadimed Corporation had a net margin of 11.61% and a return on equity of 8.98%. The company had revenue of $5.50 million for the quarter, compared to analysts’ expectations of $5.41 million. During the same quarter in the prior year, the company posted $0.24 earnings per share. iRadimed Corporation’s revenue for the quarter was down 44.4% compared to the same quarter last year. On average, analysts expect iRadimed Corporation to post $0.13 EPS for the current fiscal year and $0.23 EPS for the next fiscal year.

iRadimed Corporation (NASDAQ IRMD) opened at 10.20 on Monday. The firm has a market cap of $107.94 million, a PE ratio of 42.68 and a beta of 1.47. iRadimed Corporation has a 52-week low of $7.85 and a 52-week high of $14.24. The firm has a 50-day moving average of $10.00 and a 200-day moving average of $9.14.

TRADEMARK VIOLATION WARNING: “iRadimed Corporation (IRMD) Scheduled to Post Quarterly Earnings on Monday” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.americanbankingnews.com/2017/10/23/iradimed-corporation-irmd-scheduled-to-post-quarterly-earnings-on-monday.html.

IRMD has been the subject of several recent analyst reports. Zacks Investment Research upgraded iRadimed Corporation from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a report on Friday, August 4th. Roth Capital upgraded iRadimed Corporation from a “neutral” rating to a “buy” rating and lifted their price target for the company from $9.00 to $12.00 in a report on Monday, July 31st. Finally, ValuEngine upgraded iRadimed Corporation from a “sell” rating to a “hold” rating in a report on Friday, October 6th.

iRadimed Corporation Company Profile

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.

Earnings History for iRadimed Corporation (NASDAQ:IRMD)

Receive News & Ratings for iRadimed Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed Corporation and related companies with MarketBeat.com's FREE daily email newsletter.